Mode
Text Size
Log in / Sign up
N/A Completed N=771 Randomized Triple-blind Prevention

VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture (VITAL)

Bone Density · Body Composition · Bone Health
Source: ClinicalTrials.gov NCT01747447 ↗
Enrolled (actual)
771
Serious AEs
9.9%
Results posted
Mar 2021
Primary outcomePrimary: Change in Bone Density — 1.02; 1.02; 1.02; 1.02 g/cm^2

Summary

The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or fish oil (1 gram of omega-3 fatty acids) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among a sub-cohort of 771 participants in VITAL and will test the efficacy and safety of high-dose vitamin D supplementation vs. placebo on skeletal health and body composition.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Bone Density
1.02; 1.02; 1.02; 1.02; 1.03; 1.03
PRIMARY
Bone Turnover P1NP
49.99; 49.29; 50.25; 48.99; 48.28; 49.04
PRIMARY
Bone Turnover Beta Crosslaps
0.40; 0.41; 0.41; 0.40; 0.40; 0.42
SECONDARY
Change in Bone Structure
369.68; 373.90; 371.28; 372.29; 376.24; 382.25

Eligibility Criteria

Participants in VITAL (NCT 01169259) who meet the following criteria are eligible to participate in this ancillary study:

  • Those who are using bisphosphonates currently or within the past 2 years, or other bone-active medications currently or within the past year are not eligible for this study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01747447). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search